Showing 6921-6930 of 7243 results for "".
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- AcneFree Products with Micro-Benzoyl Peroxide Now Availablehttps://practicaldermatology.com/news/20130430-acnefree_products_with_micro-benzoyl_peroxide_now_available/2459553/Formulated with Advanced Micro-Benzoyl Peroxide, new AcneFree Clear Skin Products from Valeant Consumer Products are formulated to effectively target acne with less irritation. Three kits are available: The AcneFree 24 Hour Acne Clearing System (AcneFree
- Restoration's ARTAS Earns Edison Gold Medal for Innovationhttps://practicaldermatology.com/news/20130430-restorations_artas_earns_edison_gold_medal_for_innovation/2459554/Restoration Robotics, Inc.'s ARTAS® System was honored with the Gold medal at the 26th Edison Awards, the international awards ceremony honoring innovators and innovation, in the science/medical category. The Edison Awards celebrate human creati
- Me Smooth Debuts on QVChttps://practicaldermatology.com/news/20130429-me_smooth_debuts_on_qvc/2459557/Syneron Beauty Inc. introduced its new me smooth at-home professional hair removal system on QVC this week. The device includes a travel bag and an additional elos cartridge to deliver effective removal of unwanted hair for all skin tones, accordi
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- Angela Bennett Appointed as La Roche-Posay VPhttps://practicaldermatology.com/news/20130418-angela_bennett_appointed_as_la_roche-posay_vp/2459561/L'Oréal USA named Angela Bennett the Vice President of La Roche-Posay. A graduate of Loyola University in Baltimore, MD where she earned a degree in Business Administration, Bennett brings a wealth of experience, having worked with many global brands and has established solid relationships wi
- Web‐Based Supply Chain Management Software Launchedhttps://practicaldermatology.com/news/20130418-webbased_supply_chain_management_software_launched/2459562/Aesyntix Health, Inc. launched the Aesyntix Inventory Management (AIM), a web‐based inventory and automated ordering system to enhance its dermatology supply chain management platform. Specifically for dermatology inventory management, AIM helps
- FDA Approves New Corticosteroid Spray for Psoriasishttps://practicaldermatology.com/news/20130415-fda_approves_new_corticosteroid_spray_for_psoriasis/2459564/The FDA has approved Topicort® (desoximetasone) Topical Spray, 0.25%, for the treatment of plaque psoriasis. According manufacturer Taro Pharmaceuticals, Topicort Spray is indicated for patients 18 years of age or older.
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest